Clin Exp Med (2017) 17:415–416 DOI 10.1007/s10238-016-0433-2 LETTER TO THE EDITOR Vismodegib and risk of cholestatic injury: should we screen candidate patients? 1 2 1 2 • • • • Michelangelo Vestita Lucia Lospalluti Giuseppe Giudice Domenico Bonamonte 3 2 Ignazio Rossiello Angela Filoni Received: 15 July 2016 / Accepted: 24 July 2016 / Published online: 2 August 2016 Springer International Publishing Switzerland 2016 Dear Sir, tomography, magnetic resonance imaging and endoscopic retrograde cholangiopancreatography. Periportal edema, We have read with interest the paper of Ash et al.  along with increased liver volume and mild dilatation of concerning vismodegib-related cholestatic liver injury. We the intrahepatic bile ducts, was noticed (Fig. 1). Minute would like to report our experience with a 71-year-old lithiasic formations were present in the gallbladder, patient who underwent vismodegib therapy for 11 spread choledochus and cystic duct (Fig. 2; Suppl Fig. 1, 2). A cutaneous basal cell carcinoma, of which 4 were recurring single, larger, previously documented, 15 mm lithiasic lesions, and developed intense jaundice by severe element was also evident in the gallbladder. Ash et al.  cholestasis and acute liver injury after 3 months of vis- reason on the potential ability of vismodegib to
Clinical and Experimental Medicine – Springer Journals
Published: Aug 2, 2016
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera